epithelial and glomerular microvascular endothelial cells than untargeted ELP. Importantly, even high doses of KTP-ELP had no adverse effects on renal function nor induced renal parenchymal damage, underscoring the safety in the treatment of renal diseases. Therefore, these observations strongly suggest unique and novel therapeutic potential for KTP-ELP as a promising candidate for kidney-targeted drug delivery.
ELPs are large, biodegradable, nonimmunogenic, and highly manipulable biopolymers that act as carriers to improve drug pharmacokinetics and targeting (8) . Interestingly, ELPs accumulate at high levels in the kidneys, and their protein-based nature facilitates their modification for fusion with peptides. Indeed, stabilization and kidney accumulation achieved by fusing ELP with the pro-angiogenic vascular endothelial growth factor ameliorates microvascular rarefaction and improves renal function in swine renovascular disease, underscoring the potential of ELPs as drug delivery vectors for renal repair (3). The present study extends these observations, demonstrating that their combination with KTPs enhances ELP intrarenal distribution and binding to human renal cells.
An important strength of this study is the use of a largeanimal model to confirm the potential of KTP-ELP to direct protein therapeutics to the kidney. The anatomy and physiology of the swine kidney is very similar to that of humans. Therefore, this strategy opens up the possibility of developing future targeted therapeutic interventions for patients with renal disease. Additional applications of this technology include KTP-ELP labeling with tracers for imaging studies, which may serve as markers of renal function.
In summary, advances in drug development have propelled translational and clinical studies testing the efficacy of novel compounds to attenuate renal injury and prevent progressive functional decline. Such approaches target important pathogenic mechanisms of CKD, including inflammation, apoptosis, oxidative stress, and fibrosis, which compromise the integrity and function of several renal cell types. The study by Bidwell et. al. (2) supports the potential of a novel drug delivery vector to direct protein therapeutics to human podocytes and proximal tubule epithelial and glomerular microvascular endothelial cells. Only the future will tell us whether renoprotective drugs would benefit from the KTP-ELP construct to take a ride to renal repair.
